Scientists are trying to find a new way to produce the nutritional fatty acids called Omega 3 that are currently sourced from fish oil from the world’s declining natural fish stocks.
In a groundbreaking branch of new science – synthetic biology – the team at The University of Nottingham’s Synthetic Biology Research Centre are working with biotechnology company CHAIN Biotech and industry partner Calysta, Inc. to develop microbial technology that uses microorganisms to ferment methane gas into valuable nutritional supplements.
The pioneering project is called PUFA (polyunsaturated fatty acids). It will run for a year and is being funded by industrial biotechnology catalyst grants from InnovateUK and the BBSRC with potential further significant scaling up investment from Calysta, a sustainable nutrition company based in the US.
Omega 3 fatty acids are essential for the growth, development and healthy maintenance of the brain and are incorporated in many kinds of foods and infant nutrition products as well as animal feed and health products. Currently Omega 3 fatty acids are sourced from fish oils, but wild fish stocks are under pressure and there is an urgency to find alternative sources that are both sustainable and economical.
Leading the research at Nottingham’s Synthetic Biology Research Centre, Professor Nigel Minton said: “We specialise in the use of fermentation of certain gases to produce sustainable industrial chemicals and biofuels, and now through this project to produce vital feedstock ingredients like Omega 3 fatty acids. We will be engineering the Methanococcus microbe to produce polyunsaturated fatty acids from a cheap and replenishable feedstock – methane gas. There are huge potential benefits in terms of reducing dependency on fishing and also creating a new use for a plentiful gas that has a harmful effect on the environment if unharnessed. Methane is a low cost and sustainable feedstock that can be produced from a variety of renewable sources, including anaerobic digestion which is now prevalent in the UK and EU.”
High demand product
Dr Basil Omar, Chief Commercial Officer at CHAIN Biotech Ltd said: “This is a great example of how publicly funded early stage research is being leveraged and commercially exploited with an industry partner to scale up successful discoveries made in the lab. This highly innovative project will draw upon CHAIN’s world leading expertise in Synthetic Biology to improve production characteristics by targeting both cell growth and product yield simultaneously with a focus on Omega 3 fatty acids. We hope it will offer a cheaper route to a high demand product with positive environmental and social knock on effects.”
Calysta, the project’s commercial partner, specialise in the production of microbial proteins for the commercial fish feed and livestock markets. Microbial proteins are already used to make foods like the popular savoury spreads made from yeast extract. Fish farming is growing in response to increased global demand for seafood and Calysta has developed and is commercialising a new patented product called FeedKind™ protein to provide a sustainable fish food ingredient for the fish farming industry. The company will offer a fast track to scaling up of the PUFA manufacturing process. Calysta is based in California and will open a market introduction facility for FeedKind in Teesside, England, later this year. A commercial-scale plant in the US is expected to come online in 2018.
The Latest on: Synthetic biology
via Google News
The Latest on: Synthetic biology
- The Genome Foundry ushers Canada into the era of automated genetic engineering on February 19, 2019 at 9:18 am
You need more computational power and you need more automation,” says Vincent Martin, professor of biology and co-director of Concordia’s Centre for Applied Synthetic Biology. Testing hundreds of gene... […]
- In Vitro Impossible on February 18, 2019 at 4:50 am
In a wide range of biological interventions, from synthetic biology through tissue engineering and all the way up to neuroengineering, what I find really problematic is what I refer to as “the illusio... […]
- VC Daily: Inside the (Subscription) Box | Bold Bet on Synthetic Biology’s Upstarts on February 14, 2019 at 5:46 am
Good day. Johnson & Johnson’s $3.4 billion cash deal to buy Auris Health Inc., the largest acquisition of a venture-backed medical-device company, could have far-reaching effects across the industry. ... […]
- Synthetic Biology Market Size by 2025: Top Players- Amyris, DuPont, GenScript USA, Intrexon, Novozymes, Royal DSM on February 14, 2019 at 3:30 am
This report studies the global market size of Synthetic Biology in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of ... […]
- Mack’s Take: Labs Aim to Power Synthetic Biology Startups on February 13, 2019 at 8:52 pm
The excitement over the promise of synthetic biology has drawn considerable investor attention in recent years. A new generation of scientists is using high-powered tools like artificial intelligence ... […]
- Synthetic Biology Market Growing Technology, Trends and Business Opportunities by 2025 on February 13, 2019 at 2:17 am
Feb 13, 2019 (Heraldkeeper via COMTEX) -- The Synthetic Biology Market report aims to provide a 360-degree view of the market in terms of cutting-edge technology, key developments, drivers, restraints ... […]
- Biology by Design: Applying Gigabases of DNA to Bioengineering on February 8, 2019 at 2:01 pm
Join us for this GEN webinar, where you will discover new ways DNA synthesis can be applied to bioengineering, in addition to learning about innovative synthetic biology applications using automation ... […]
- IDT supports innovative synthetic biology start-ups with grant program on February 8, 2019 at 3:33 am
Demonstrating its commitment to advocating for synthetic biology research, Integrated DNA Technologies’ (IDT) Synthetic Biology Start-up Grant Program has once again benefited innovative start-ups in ... […]
- Molecular Biology Enzymes, Kits & Reagents Market Qualitative Insights, Key Enhancement, Share Forecasted To 2027 on February 7, 2019 at 11:32 pm
Based on application, the global target market is segmented based on polymerase chain reaction, sequencing, cloning, epigenetics, restriction digestion, and synthetic biology. The polymerase chain rea... […]
- Partnering to scale synthetic biology STEM education for K12 on February 7, 2019 at 12:20 am
Amino Labs, a leading developer of practice-based synthetic biology (syn-bio) technologies, announced it has partnered with MindFuel, a leading organization in educational science, technology, enginee... […]
via Bing News